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insulinaemia during critical illness: a prospective,
double blind, randomised, crossover study
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Michael A Nauck6, Michael Horowitz2,3 and Adam M Deane1,4Abstract
Introduction: Insulin is used to treat hyperglycaemia in critically ill patients but can cause hypoglycaemia, which is
associated with poorer outcomes. In health glucose-dependent insulinotropic polypeptide (GIP) is a potent glucose-
lowering peptide that does not cause hypoglycaemia. The objectives of this study were to determine the effects of
exogenous GIP infusion on blood glucose concentrations, glucose absorption, insulinaemia and gastric emptying in
critically ill patients without known diabetes.
Methods: A total of 20 ventilated patients (Median age 61 (range: 22 to 79) years, APACHE II 21.5 (17 to 26), BMI 28
(21 to 40) kg/m2) without known diabetes were studied on two consecutive days in a randomised, double blind,
placebo controlled, cross-over fashion. Intravenous GIP (4 pmol/kg/min) or placebo (0.9% saline) was infused
between T = −60 to 300 minutes. At T0, 100 ml of liquid nutrient (2 kcal/ml) containing 3-O-Methylglucose (3-OMG),
100 mcg of Octanoic acid and 20 MBq Tc-99 m Calcium Phytate, was administered via a nasogastric tube. Blood
glucose and serum 3-OMG (an index of glucose absorption) concentrations were measured. Gastric emptying,
insulin and glucagon levels and plasma GIP concentrations were also measured.
Results: While administration of GIP increased plasma GIP concentrations three- to four-fold (T = −60 23.9 (16.5 to
36.7) versus T = 0 84.2 (65.3 to 111.1); P <0.001) and plasma glucagon (iAUC300 4217 (1891 to 7715) versus 1232 (293
to 4545) pg/ml.300 minutes; P = 0.04), there were no effects on postprandial blood glucose (AUC300 2843 (2568 to
3338) versus 2819 (2550 to 3497) mmol/L.300 minutes; P = 0.86), gastric emptying (AUC300 15611 (10993 to 18062)
versus 15660 (9694 to 22618) %.300 minutes; P = 0.61), glucose absorption (AUC300 50.6 (22.3 to 74.2) versus 64.3
(9.9 to 96.3) mmol/L.300 minutes; P = 0.62) or plasma insulin (AUC300 3945 (2280 to 6731) versus 3479 (2316 to
6081) mU/L.300 minutes; P = 0.76).
Conclusions: In contrast to its profound insulinotropic effect in health, the administration of GIP at pharmacological
doses does not appear to affect glycaemia, gastric emptying, glucose absorption or insulinaemia in the critically ill
patient.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12612000488808. Registered 3 May 2012.* Correspondence: p_kar@hotmail.com
1Intensive Care Unit, Level 4, Emergency Services Building, Royal Adelaide
Hospital, North Terrace, Adelaide, South Australia 5000, Australia
Full list of author information is available at the end of the article
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Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
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Hyperglycaemia frequently occurs in the critically ill pa-
tient, is exacerbated by feeding, and is associated with
adverse outcomes [1,2]. Outcomes appear particularly
poor in patients without pre-existing diabetes, which ac-
counts for the majority of critically ill patients with
hyperglycaemia [1,3-6]. When blood glucose concentra-
tions are elevated, current guidelines recommend ad-
ministering exogenous insulin, which is associated with
substantial risks of hypoglycaemia and perturbations in
blood glucose [4,7,8]. Both hypoglycaemia and glycaemic
variability may be more harmful than hyperglycaemia
[9-11]. Accordingly, for hyperglycaemic critically ill pa-
tients who are not known to have diabetes there is a
compelling rationale to maintain blood glucose within a
narrow range that does not cause hypoglycaemia and
limits blood glucose variability [4,12].
The incretin effect refers to the greater insulinotropic
response to an oral/enteral glucose load when com-
pared with an intravenous glucose load. The incretin
effect is accounted for by incretin hormones, glucagon-
like peptide-1 (GLP-1) and glucose-dependent insulino-
tropic polypeptide (GIP), which are secreted from the
small intestine in response to nutrient exposure [4]. GLP-
1 stimulates insulin and suppresses glucagon secretion
[13]. GIP is also insulinotropic but, in contrast, may
stimulate glucagon secretion, particularly at a lower blood
glucose level [14]. Importantly, the effects of GLP-1 and
GIP are glucose dependent, so that exogenous administra-
tion of GLP-1 and/or GIP, even at pharmacological doses,
does not cause hypoglycaemia [14]. For this reason there
is considerable interest in the potential use of GLP-1 and
GIP in the management of hyperglycaemia in the critically
ill patient [4,15].
Our group has reported that exogenous GLP-1 retains
its potent glucose-lowering effect in the critically ill pa-
tient during enteral feeding because it stimulates insulin
secretion and slows gastric emptying [16-18]. Slower
gastric emptying may be undesirable, however, particularly
in relation to the potential to exacerbate gastroesophageal
reflux [17] and compromise enteral feeding [19,20].
In health, physiological doses of GIP (~1 pmol/kg/
minute) are well tolerated and pharmacological doses
(≥1.5 pmol/kg/minute) may accelerate gastric emptying
[21], with even greater doses (~4 pmol/kg/minute) having
potent insulinotropic effects [22-24]. Additionally, GIP
may promote weight gain via increased glucose absorption
and/or a trophic effect on adipose tissue [25].
The effects of GIP on insulin and glucagon are af-
fected acutely by perturbations in glycaemia. For ex-
ample, at normal (6 to 10 mmol/l) and low (≈2.5 mmol/l)
blood glucose concentrations, exogenous GIP stimulates
glucagon secretion and has negligible effects on insulin se-
cretion; whereas at elevated (≥12.0 mmol/l) blood glucoseconcentrations, GIP appears to have no effect on glucagon
secretion and is profoundly insulinotropic [22,26]. Given
that GIP has a bi-directional glucose-dependent effect on
glucagon secretion and has been reported to have a stabi-
lising effect on glycaemia in patients with type 2 diabetes
[27], exogenous GIP could potentially reduce glycaemic
variability in this cohort.
Our group has reported that, in the critically ill pa-
tient, GIP at a dose considered slightly above postpran-
dial physiological concentrations (2 pmol/kg/minute)
when administered with another potent insulinotropic
hormone, GLP-1, does not have an additive glucose-
lowering effect [20]. However, the effects of GIP when
administered as a sole agent at doses that are pharmaco-
logical in this group are unknown. Given that GIP may
have a more favourable effect profile on gastric emptying
and glucose absorption, it is important to determine the
effects of GIP in the critically ill patient.
We hypothesised that exogenous GIP will lower fast-
ing and nutrient-stimulated glycaemia by stimulating
insulin secretion, while modestly accelerating gastric
emptying, and increasing the rate of glucose absorption.
The objectives of this study were to determine the acute
effects of exogenous GIP (4 pmol/kg/minute) on gly-
caemia, gastric emptying, glucose absorption, and insulin




Critically ill patients without known diabetes, with blood
glucose concentration >7.1 mmol/l when fasting and/or
>10 mmol/l during enteral feeding, and who were ex-
pected to remain mechanically ventilated via a tracheal
tube for at least 48 hours were studied between April and
December 2012. All patients had an arterial catheter in
situ, which is routine care for ventilated patients admitted
to the Royal Adelaide Hospital Intensive Care Unit, and
this was used for blood sampling. Patients were excluded
due to pregnancy, anaemia (haemoglobin <80 g/l), age
(<18 years), contraindication to enteral feeding, previous
surgery on the small intestine or any gastrointestinal sur-
gery during their then current hospital admission.
Protocol
This was a prospective, randomised, double-blind, cross-
over study. Patients were studied on two consecutive
days, on which they received intravenous GIP (4 pmol/
kg/minute) or placebo (0.9% saline) at the commence-
ment of the study period (T–60) (Figure 1). Patients
were fasted for 4 hours and exogenous insulin (Actrapid)
was ceased 2 hours prior to each study. Patient weight
was measured using bed scales (MPWS; A&D Medical,
Sydney, NSW, Australia). Synthetic GIP (Bachem, Weil
Figure 1 Protocol of the study. GIP, glucose-dependent insulinotropic polypeptide; IV, intravenous; mcg, micrograms.
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Adelaide Hospital Department of Pharmacy in 0.9% saline.
The Department of Pharmacy was also responsible for
computer-generated randomisation. While study drugs
appeared identical, treatment blinding was ensured by the
use of plastic coverings over all solutions. Study drugs
were delivered through low-absorbance tubing (Verasafe;
Carefusion, San Diego, CA, USA) to prevent protein bind-
ing [16-18]. The randomisation schedule was kept in a
locked facility within the Department of Pharmacy and
the investigators had no access to the schedule during the
study period. All solutions were given via a central venous
catheter at 1 ml/minute using an infusion pump (Alaris;
Cardinal Health, Sydney, NSW, Australia). Sixty minutes
after the study drug was commenced (that is, at T0), a li-
quid nutrient meal was administered via nasogastric tube
over 5 minutes. The meal contained 100 ml TwoCal®
(2 kcal/ml; Abbot Nutrition, Botany, NSW, Australia), a
mixed nutrient liquid containing carbohydrate (43%), fat
(40%), and protein (17%), as well as 3 g 3-O-methyglucose
(3-OMG; Sigma-Aldrich, Sydney, NSW, Australia) dis-
solved in 5 ml water, 100 μg octanoic acid (Sigma-
Aldrich), and 20 MBq technetium-99 m calcium phytate
(Radpharm Scientific, Belconnen, ACT, Australia). Pa-
tients were studied for 360 minutes (from T–60 to T300)
in total during each study period.
This study was approved by the Research Ethics Com-
mittee of the Royal Adelaide Hospital and the protocol
was registered with the Australian New Zealand Clinical
Trials Registry (ACTRN number 12612000488808). Pa-
tients were unconscious when enrolled and consent was
therefore obtained from and signed by their next of kin.
Data collection
Arterial blood samples (5 ml) were collected immedi-
ately prior to administration of the study drug (T–60)
and the intragastric meal (T0), and at 15-minute inter-
vals from T0 to T60, and then at 30-minute intervals
until T300, for measurements of serum 3-OMG and
blood glucose concentrations. Samples for measurementof serum insulin were collected at T–60, 0, 15, 30, 45,
60, 90, 120, 150, 180, 210, 240 and 300 minutes, for
serum glucagon at T–60, 0, 30, 60, 120, 180, 240 and
300 minutes, and for plasma GIP at T–60, 0, 60, 120
and 300 minutes. Blood was stored in ice at all times.
Serum was separated by centrifugation within 30 minutes
of completion of the study (3,200 rpm for 15 minutes at
4°C) and then stored at –70°C until assayed. Expiratory
breath samples were collected as described previously
[17]. Left anterior oblique (45°) images were acquired
using a mobile gamma camera (Digirad, Poway, CA,
USA) in 3-minute dynamic frames from T0 to T300
with patients positioned supine [28].
Blood glucose, glucose absorption and insulin, glucagon
and glucose-dependent insulinotropic polypeptide
Blood glucose concentrations were measured and re-
corded immediately, by the investigators, using a blood
gas analyser (ABL800 FLEX; Radiometer, Copenhagen,
Denmark) [20]. The monosaccharide 3-OMG is absorbed
from the small intestine via the same transporters as glu-
cose, but is not metabolised [28,29], and measurement of
serum 3-OMG concentrations provides an accurate meas-
ure of glucose absorption in healthy individuals and the
critically ill [28,29]. Serum 3-OMG concentrations were
measured using liquid chromatography/mass spectros-
copy, with an assay sensitivity of 0.0103 mmol/l [17].
When the baseline (T–60) serum concentrations of 3-
OMG on day 2 were greater than the assay sensitivity (that
is, fasting serum 3-OMG concentration >0.0103 mmol/l),
the concentration at T–60 was referenced as zero for sub-
sequent analysis [28].
Serum insulin was measured by enzyme-linked im-
munosorbent assay (10-1113; Mercodia, Uppsala, Sweden),
which had an interassay coefficient of variation of 5.4%
and an intraassay coefficient of variation of 2.7 [20]. Serum
glucagon was measured via radioimmunoassay (GL-32 K;
Millipore, Billerica, MA, USA). The minimum detectable
limit was 20 pg/ml, with an interassay coefficient of vari-
ation of 6.1% and an intraassay coefficient of variation of
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immunoassay (Perkin Elmer, Boston, MA, USA), with an
interassay coefficient of variation of 8.3% and an intraassay
coefficient of variation of 6.3% [20].
Glycated haemoglobin
Glycated haemoglobin was determined using high-
performance liquid chromatography [20]. Unrecognised
diabetes was defined as glycated haemoglobin >6.5%
(48 mmol/mol) in patients with no history of diabetes [6].
Gastric emptying
Gastric emptying was measured using two different
techniques: scintigraphy – although the gold standard,
this technique requires the availability of both a mobile
gamma camera and a trained nuclear medicine tech-
nologist, and these could not be guaranteed to be avail-
able on every study day; and radioisotope (13C-octanoic
breath test), which was available for every study day.
Gastric scintigraphy requires mixing of a radioisotope
(20 MBq technetium-99m calcium phytate) with a meal
that is administered via nasogastric tube. A gamma cam-
era then records images of the labelled meal, which indi-
cates the percentage of the meal remaining within the
stomach at any time point. The greater the percentage
retained within the stomach, the slower gastric empty-
ing. Scintigraphic data were analysed by a nuclear medi-
cine technologist (KLJ) blinded to the study conditions.
Radioisotopic data were corrected for subject movement
and radionuclide decay. A region of interest was drawn
around the total stomach, gastric emptying curves gen-
erated over time, and intragastric retention derived at
15-minute intervals from T0 to 300 minutes.
The 13C-octanoic breath test was performed as described
previously [17,28]. Data were expressed as the gastric
emptying coefficient, a global measure of gastric emptying;
a higher number is indicative of more rapid emptying [17].
Statistical analysis
The sample size was based on calculations that 20 pa-
tients would provide 80% power, at a two-sided α-level
of 0.05, to detect a minimum difference in postprandial
glycaemia (glucose levels in the blood) of 290 mmol/l.
300 minutes between groups, which was predefined as
clinically significant, and was based on the within-
patient standard deviation of glycaemia as mmol/
l.300 minutes [17].
While differences between GIP and placebo were dis-
tributed normally, most of the raw data were skewed.
Accordingly, all data are presented as median (range or
25th to 75th percentile), unless specified otherwise. Sig-
nificance was determined using nonparametric Wilcoxon
signed-rank tests. Serum 3-OMG (glucose absorption),
plasma insulin and blood glucose concentrations arepresented as areas under the concentration curve (AUCs),
and were calculated using the trapezoidal rule. Relative
glucagon response was measured by the incremental AUC
using the trapezoidal rule. The absolute glucagon change
from baseline was used to remove intrasubject variation in
baseline levels. The maximal effects of gastric emptying
were anticipated to occur in the first 60 minutes after the
meal, so this period was also chosen a priori for analyses.
All reported P values are two sided, with the 0.05 level
selected to determine significance. When significant, mul-
tiple comparisons were adjusted for using the Bonferroni–
Holm procedure. Data were evaluated for potential carry
over and/or period effects by including the order variable
in repeated-measures analysis of variance; however, there
were no order-by-treatment interactions. Between-subject
Pearson correlations were calculated on each study visit
separately between the initial rate of gastric emptying (%
gastric retention at T = 60 minutes as determined using
scintigraphy) and each of glycaemia, insulin and 3-OMG
absorption (the delta value from 0 to 60 minutes for each).
Scatter plots were examined to assess the linearity of the
relationship and Pearson’s correlation was considered ap-
propriate in each case. Steiger’s Z2* test for difference be-
tween two dependent correlations was used to compare
the correlations between the same outcomes between the
two visits. Statistical analyses were performed using SPSS
(Version 18.0) was supplied by: "The University of Adel-
aide, Adelaide, SA, Australia". An independent profes-
sional biostatistician had access to all data and verified
these analyses.
Results
Twenty-four patients were enrolled and no adverse ef-
fects (vomiting, hypoglycaemia, seizure or rash) were ob-
served with the study drug. Blood results were also
reviewed with no unexpected changes to haemoglobin,
platelets, liver function tests and electrolytes. Four pa-
tients failed to complete both study days due to tracheal
extubation (two patients), withdrawn consent (one pa-
tient) and migration of the feeding tube into the small
intestine (one patient). Data from these patients were
not included in the analyses. Demographic details for pa-
tients completing the study are summarised in Table 1.
One patient was diagnosed with unrecognised diabetes
with a glycated haemoglobin of 9.1% (76 mmol/mol).
Peak fasting and peak postprandial glucose concentra-
tions along with administered medications, sedation
score and temperature were also recorded (Table 1).
Blood glucose, glucose absorption and hormones
Baseline blood glucose concentrations were similar on
both days (at T − 60: GIP 7.5 (6.5 to 9.5) vs. control 7.6
(7.0 to 9.4) mmol/l; P = 0.68). GIP had no effect on
blood glucose before the meal (at T0: 8.1 (9.6 to 9.0) vs.
Table 1 Patient characteristics
Age (years) 62 (22 to 79)
Sex Male: 12, female: 8
Body mass index (kg/m2) 28 (21 to 40)
APACHE II (score) 21.5 (17 to 26)
Length of ICU admission prior to study day 1 (days) 3.0 (1 to 16)
Glycated haemoglobin (HbA1c)
% 5.9 (5.3 to 9.1)
mmol/mol 40.5 (34 to 76)
Calories delivered in previous 24 hours (kcal) 885 (0 to 1,680)
Feed tolerant (patients) 14
Blood glucose concentration (mmol/l)
Peak fasting 9.5 (6.6 to 14.2)














Peak dose (units/hour) 5.5 (2.5 to 10.5)
Dose in previous 24 hours (units) 42.4 (15.0 to 117.0)
Corticosteroid 7
Hydrocortisone dose (or equivalent)
on study day (mg/day)
200 (50 to 1,000)
RASS sedation score −4 (−2 to –5)








Data presented as median (range); n = 20. APACHE, Acute Physiology and
Chronic Health Evaluation; RASS, Richmond Agitation Sedation Scale. aPatients
were on multiple medications during the course of the study.
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blood glucose concentration after the meal (Figure 2A),
peaking between 60 and 90 minutes, but GIP had noeffect on either peak glucose concentrations (9.4 (8.3 to
11.9) vs. 9.8 (8.4 to 11.8) mmol/l; P = 0.73) or the overall
glycaemic response (AUC300: 2,843 (2,568 to 3,338) vs.
2,819 (2,550 to 3,497) mmol/l.300 minutes; P = 0.86).
Data were similar when the patient with unrecognised
diabetes was excluded (AUC300: 2,991 (2,469 to 3,639)
vs. 2,781 (2,578 to 3,738) mmol/l.300 minutes P = 0.74).
Glucose absorption was unaffected by GIP administra-
tion (AUC300: 50.6 (22.3 to 74.2) vs. 64.3 (9.9 to 96.3)
mmol/l.300 minutes; P = 0.62) (Figure 2B).
Insulin concentrations were similar at baseline on both
study days (at T − 60: 7.9 (4.8 to 12.0) vs. 6.4 (2.9 to
13.5) mU/l; P = 0.75). There was a postprandial rise in
insulin concentrations, peaking between 60 and 90 mi-
nutes. Overall insulin response was not affected by GIP
(AUC300: 3,945 (2,280 to 6,731) vs. 3,479 (2,316 to 6,081)
mU/l.300 minutes; P = 0.76) (Figure 2C). Plasma GIP
concentrations were comparable at baseline (at T − 60:
23.9 (16.5 to 36.7) vs. 23.0 (15.6 to 41.9) pmol/l; P =
0.96) and the exogenous GIP infusion resulted in a
threefold to fourfold increase above physiological con-
centrations (P <0.001, Figure 2D).
Glucagon concentrations were also similar at baseline
(at T − 60: 104.5 (85.1 to 236.6) vs. 115.7 (85.8 to 287.6)
pg/ml; P = 0.37) and prior to the meal (at T0: 128.5 (99.4
to 290.8) vs. 112.5 (82.8 to 292.9) pg/ml; P = 0.08). How-
ever, the postprandial increment was significantly in-
creased with GIP as compared with control (incremental
AUC300: 4,217 (1,891 to 7,715) vs. 1,232 (293 to 4,545)
pg/ml.300 minutes; P = 0.04) (Figure 2E).
Gastric emptying
Paired scintigraphic data were collected in 18 patients
and breath test data were available for all patients. Using
scintigraphy, 100% of the meal remained in the stomach
at T = 300 minutes in one patient on both study days
and in two other patients during either GIP or placebo,
indicative of markedly delayed gastric emptying.
GIP had no effect on intragastric retention 60 minutes
after the meal (at T60: 80 (66 to 89) vs. 84 (60 to 96)%;
P = 0.88) and at the study end (at T300: 26 (10 to 63) vs.
37 (7 to 92)%; P = 0.33), or on the overall gastric empty-
ing rate as determined using scintigraphy and breath test
techniques (Figure 3A,B).
Relationships
The change in blood glucose was related to gastric
emptying; the more rapid the emptying, the greater the
glycaemic excursion during placebo (r = 0.85; P <0.01)
and GIP (r = 0.48; P = 0.04), with the correlation signifi-
cantly stronger during placebo (z = 2.1; P = 0.04). There
was a close relationship between 3-OMG concentrations
(glucose absorption) and gastric emptying during both
placebo and GIP (Figure 4). However, the relationship
Figure 2 Effects of glucose-dependent insulinotropic polypeptide. Effects of glucose-dependent insulinotropic polypeptide (GIP; 4 pmol/kg/
minute) on: (A) glycaemia (AUC–60 to 300: GIP, 2,843 (2,468 to 3,639) vs. control, 2,819 (2,578 to 3,788) mmol/l.300 minutes; P = 0.86); (B) glucose
absorption (serum 3-O-methylglucose (3-OMG)) (AUC0 to 300: 50.6 (22.3 to 74.2) vs. 64.3 (9.9 to 96.3) mmol/l.300 minutes; P = 0.62); (C) insulin
concentrations (AUC–60 to 300: 3,945 (2,280 to 6,731) vs. 3,479 (2,499 to 5,658) mU/l.300 minutes; P = 0.76); (D) GIP concentrations (*P <0.001;
Bonferroni–Holm correction for all time points); (E) glucagon concentrations (incremental AUC–60 to 300: 4,217 (1,891 to 7,715) vs. 1,232 (293 to
4,545) pg/ml.300 minutes; P = 0.04). Data are median (25th to 75th percentile), analysed using Wilcoxon signed-rank test; n = 20. AUC, area under
the concentration curve.
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Figure 3 Gastric emptying. Effect of glucose-dependent insulinotropic
polypeptide (GIP) on gastric emptying as measured using: (A) retention
of gastric contents over time (scintigraphic technique) (AUC0 to 300: GIP,
15,611 (10,993 to 18,062) vs. placebo, 15,660 (9,694 to 22,618)%.300
minutes; P = 0.61; n = 18); and (B) gastric emptying coefficient
(labelled breath test) (1.98 (1.60 to 2.50) vs. 2.01 (1.14 to 2.81); P = 0.99;
n = 20). Data are median (25th to 75th percentile); analysed using
Wilcoxon’s signed-rank test. AUC, area under the concentration curve.
Figure 4 Relationship between glucose absorption and gastric
emptying. Relationship between 3-O-methylglucose (3-OMG)
concentrations (glucose absorption) and gastric emptying (retention
at T = 60; scintigraphy) during glucose-dependent insulinotropic
polypeptide (GIP; r = 0.66; P <0.01) and placebo (r = 0.95; P <0.01).
Data are analysed between subjects using Pearson correlations;
n = 18.
Kar et al. Critical Care  (2015) 19:20 Page 7 of 10was significantly stronger during placebo (z = 3.1, P <0.01).
Relatively more rapid gastric emptying was also associated
with increased insulin secretion during placebo (r = 0.48;
P = 0.04) and GIP (r = 0.47; P <0.05), with no difference
between placebo and GIP (z = 0.02, P = 0.98).
Discussion
This study indicates in patients with critical illness-
associated hyperglycaemia that acute intravenous ad-
ministration of GIP at pharmacological doses has no
insulinotropic activity, does not reduce elevated blood
glucose concentrations but does cause a significant
postprandial rise in glucagon.
The mechanism(s) underlying the absence of a glucose-
lowering effect of GIP are uncertain. Based on the known
effects of GIP in ambulant populations, the precedingacute glycaemic disturbance associated with critical illness
is probably important. Chronic hyperglycaemia has been
shown to profoundly diminish the insulinotropic effect of
GIP; that is, the insulinotropic effect is almost abolished in
patients with longstanding hyperglycaemia [24,30,31]. In
patients with type 2 diabetes, 4 weeks of intensive insulin
therapy aiming for near-normal glycaemia partially re-
established the insulinotropic properties of GIP [32].
While the duration of normoglycaemia or hyperglycaemia
required to modify the response to GIP in humans re-
mains to be determined, in cell cultures as little as 24 hours
exposure to glucose concentrations >11 mmol/l leads to a
substantial downregulation of GIP receptors on beta cells
[33]. However, with respect to this study, in the absence of
data from patients without hyperglycaemia, this hypoth-
esis is difficult to prove.
The critically ill patients in this study were studied
relatively early in their admission and the objective prior
to the intervention was to restrict glucose concentra-
tions to <10 mmol/l while in the ICU. These features are
consistent with the concept that the magnitude and dur-
ation of hyperglycaemia required to attenuate the insuli-
notropic effect of GIP in humans is relatively modest.
While hyperglycaemia may possibly be an important
modulator, the possibility that the response to GIP is
caused by critical illness per se cannot be excluded.
Increased secretion of cytokines and other counter-
regulatory hormones are prominent features of critical
illness-associated hyperglycaemia [1,4] and these cyto-
kines possibly downregulate responsiveness to GIP in
the critically ill independent of hyperglycaemia.
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may be due to the effect of GIP on glucagon. Exogenous
GIP is known to be glucagonotropic at normal and low
blood glucose concentrations, and therefore the rise in
levels of glucagon within this study may have contrib-
uted to the absence of blood glucose lowering.
It has been reported in healthy subjects that exogen-
ous GIP attenuates postprandial glycaemia while mildly
accelerating gastric emptying [21], but in this study gas-
tric emptying was unaffected by GIP during critical ill-
ness. A possible explanation for this difference is that
the acceleration of gastric emptying observed in the
former study may have resulted from the insulinotropic
effects of GIP, which, by lowering blood glucose concen-
trations, had a mild gastrokinetic effect, given that sys-
temic glycaemia is a major determinant of the emptying
rate [34]. However, blood glucose concentrations were
unaffected in the study population and therefore the ef-
fect of GIP on the gastric emptying rate was expected to
be somewhat marginal.
The effect of GIP on nutrient absorption in the critic-
ally ill was of particular interest. Glucose absorption is
markedly diminished in the critically ill patient and
downregulation of the sodium–glucose co-transporter 1
appears to be pivotal [29,35]. In isolated mice jejunum,
GIP increases glucose transport across the lumen, via
upregulation of sodium–glucose co-transporter 1 [25].
In this study, glucose absorption did not appear to be af-
fected by GIP. However, an effect of GIP on nutrient
absorption cannot be completely dismissed because
nutrient was delivered into the stomach and small intes-
tinal nutrient absorption can only be accurately mea-
sured when nutrient is delivered distal to the pylorus
[35]. The relationship between glucose absorption and
gastric emptying being weaker during GIP suggests that
factors distal to the pylorus may be relevant. Further-
more, the study period was relatively short and may have
been insufficient to detect any effect of sodium–glucose
co-transporter 1 expression and subsequent functional
(absorptive) outcomes.
A particular strength of this study is that the cohort had
features consistent with acutely impaired glucose toler-
ance, although one patient was subsequently shown to
have unrecognised type 2 diabetes. In addition, median
blood glucose concentrations were ~8 mmol/l, which
should have been sufficient to stimulate an insulinotropic
effect of GIP [13]. For these reasons it is likely that the
lack of effect observed represents a true observation.
There are, however, limitations to this study. Only a
single dose of GIP was tested, and it cannot be assumed
that glycaemia will remain unaffected at greater doses.
However, GIP administered at 4 pmol/kg/minute has
substantial biological effects in both healthy individuals
and patients with diabetes, consistent with the conceptthat this amount reflects a potent pharmacological dose
[21,22,24,31,36,37] – and even at one-half the dose ad-
ministered in this study (2 pmol/kg/minute) GIP accel-
erates gastric emptying [21], suggesting that the dose
chosen was sufficient to have a pharmacological effect.
Additionally, insulin levels were measured as opposed
to C-peptide, which may be a better marker of endogen-
ous insulin production, as C-peptide analysis was cost
prohibitive.
In the current study a profound threefold to fourfold
increase in plasma GIP concentrations was evident. This
increase in plasma concentration is similar to previous
studies where a significant effect has been shown with
GIP administration in both healthy individuals [21] and
in patients with diabetes [37]. While some studies using
a similar dose have reported greater increases in plasma
GIP concentrations [24,31], this may well be explained
by the different assay techniques. Nonetheless, there is
the possibility that achieving greater GIP concentrations
may affect glycaemia differently.
The number of patients studied was relatively few,
such that it may be underpowered to show a difference
in insulin and 3-OMG concentrations. There was also
substantial heterogeneity between patients with regards
to their diagnosis and the duration of ICU admission.
However, the capacity of GLP-1 to affect glycaemia has
been observed using smaller cohorts [16,38]. The expos-
ure to exogenous GIP was relatively short (6 hours) and
it remains possible, albeit intuitively unlikely, that more
prolonged exposure to GIP would reveal an insulinotro-
pic effect.
The patients within this study had only moderate hyper-
glycaemia. There is a possibility that clamping blood glu-
cose at a higher concentration (for example, 12 mmol/l)
may have lead to administration of GIP at 4 pmol/kg/mi-
nute, causing a greater insulinotropic effect. Finally, syn-
thetic GIP currently remains an expensive product, which
limits its use for proof-of-principle studies.
Along with these limitations, other factors may influ-
ence blood glucose levels such as catecholamine infu-
sions, corticosteroid use, depth of sedation and body
temperature. These variables are common within the
critical care population, and may be confounders with
respect to this study.
Several different groups have evaluated the effects of
synthetic GLP-1, or its agonists, on glycaemia in the crit-
ically ill with – and without – antecedent type 2 dia-
betes, and there is consistent evidence that GLP-1 has a
prominent glucose-lowering effect [16-18,39]. When
evaluating this study with our previous observation – that
GIP (2 pmol/kg/minute) had no additive insulinotropic ef-
fect in the critically ill patient when administered in com-
bination with GLP-1 – it appears that future studies
should focus on the use of GLP-1 or its agonists rather
Kar et al. Critical Care  (2015) 19:20 Page 9 of 10than GIP. These observations should not, however, be ex-
trapolated to the potential use of dipeptidyl peptidase-4
inhibitors (which inhibit the enzyme that inactivates GIP
and GLP-1) to treat hyperglycaemia in the critically ill pa-
tient, because the efficacy of dipeptidyl peptidase-4 inhibi-
tors may result in part from increases in intestinal and
portal blood GLP-1 and GIP concentrations [40].
Conclusions
In critically ill patients, an acute infusion of GIP at 4
pmol/kg/minute had no effect on glycaemia, gastric
emptying, glucose absorption, insulin or glucagon secre-
tion. Because the magnitude and duration of hypergly-
caemia required to attenuate the insulinotropic effect of
GIP appears to be relatively modest, future evaluation of
the use of incretin-based approaches in the critically ill
patient should focus on GLP-1 and its agonists.
Key messages
 In the healthy individual, GIP is a potent
insulinotropic hormone leading to glucose lowering.
 In the critically ill patient, the effects of GIP are not
apparent.
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